Want to see HK:6078 full AI Analyst Report?
6078 Stock Chart & Stats
HK$12.69
HK$0.20(1.47%)
At close: 4:00 PM EST
HK$12.69
HK$0.20(1.47%)
Day’s Range― - ―
52-Week RangeHK$8.10 - HK$18.40
Previous CloseN/A
Volume2.54M
Average Volume (3M)7.15M
Market Cap
HK$5.78B
Enterprise ValueHK$6.30B
Total Cash (Recent Filing)HK$741.02M
Total Debt (Recent Filing)HK$2.45B
Price to Earnings (P/E)116.3
Beta1.46
Next Earnings
Aug 27, 2026EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding618,499,000
10 Day Avg. Volume3,556,037
30 Day Avg. Volume7,151,771
Financial Highlights & Ratios
PEG Ratio-0.58
Price to Book (P/B)1.02
Price to Sales (P/S)1.72
P/FCF Ratio14.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$19.20Price Target Upside51.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.82
Revenue Forecast (FY)HK$4.33B
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue Growth & ScaleThe company has exhibited multi-year top-line growth, reflecting expanding hospital network scale and sustained service demand. A growing revenue base and platform of hospitals create durable patient flow and cross-sell opportunities, supporting medium-term organic growth and operational leverage.
Manageable Leverage And Expanding EquityLeverage metrics are moderate with improving debt-to-equity, and total assets and equity have expanded. This balance-sheet strength supports capital investment, acquisitions, and weathering demand cycles with lower refinancing risk, preserving strategic optionality over the next several quarters.
Improving Cash GenerationConsistent positive operating cash flow and a 2025 free-cash-flow rebound indicate improving cash conversion ability versus prior years. Strengthening cash generation enhances the company's capacity to fund reinvestment, service debt, and support network expansion without relying solely on external capital.
Bears Say
Profitability Collapse In 2025A sharp drop in net margin and ROE in 2025 signals either rising costs, pricing or reimbursement pressure, or a large one-off drag. Sustained margin erosion would undermine reinvestment, returns on equity, and the economics of expanding hospital capacity, reducing long-term shareholder value.
Recent Revenue WeaknessA negative recent revenue growth metric suggests weakening patient volumes, case mix deterioration, or pricing pressure. If top-line contraction persists, it will limit operating leverage, constrain margin recovery, and slow cash flow growth, challenging medium-term strategic initiatives.
Earnings And Cash-Conversion VolatilityInconsistent cash conversion and past years with negative FCF point to volatility in working capital or reinvestment needs. Variable cash generation reduces predictability of internal funding for capex and acquisitions, complicating long-term planning and amplifying risk during profit shocks.
Hygeia Healthcare Holdings Co., Ltd. News
6078 FAQ
What was Hygeia Healthcare Holdings Co., Ltd.’s price range in the past 12 months?
Hygeia Healthcare Holdings Co., Ltd. lowest stock price was HK$8.10 and its highest was HK$18.40 in the past 12 months.
What is Hygeia Healthcare Holdings Co., Ltd.’s market cap?
Hygeia Healthcare Holdings Co., Ltd.’s market cap is HK$5.78B.
When is Hygeia Healthcare Holdings Co., Ltd.’s upcoming earnings report date?
Hygeia Healthcare Holdings Co., Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 55 days.
How were Hygeia Healthcare Holdings Co., Ltd.’s earnings last quarter?
Hygeia Healthcare Holdings Co., Ltd. released its earnings results on Mar 30, 2026. The company reported -HK$0.15 earnings per share for the quarter, missing the consensus estimate of -HK$0.139 by -HK$0.012.
Is Hygeia Healthcare Holdings Co., Ltd. overvalued?
According to Wall Street analysts Hygeia Healthcare Holdings Co., Ltd.’s price is currently Undervalued.
Does Hygeia Healthcare Holdings Co., Ltd. pay dividends?
Hygeia Healthcare Holdings Co., Ltd. pays a Annually dividend of HK$0.164 which represents an annual dividend yield of N/A. See more information on Hygeia Healthcare Holdings Co., Ltd. dividends here
What is Hygeia Healthcare Holdings Co., Ltd.’s EPS estimate?
Hygeia Healthcare Holdings Co., Ltd.’s EPS estimate is 0.35.
How many shares outstanding does Hygeia Healthcare Holdings Co., Ltd. have?
Hygeia Healthcare Holdings Co., Ltd. has 618,499,000 shares outstanding.
What happened to Hygeia Healthcare Holdings Co., Ltd.’s price movement after its last earnings report?
Hygeia Healthcare Holdings Co., Ltd. reported an EPS of -HK$0.15 in its last earnings report, missing expectations of -HK$0.139. Following the earnings report the stock price went down -0.348%.
Which hedge fund is a major shareholder of Hygeia Healthcare Holdings Co., Ltd.?
Currently, no hedge funds are holding shares in HK:6078
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hygeia Healthcare Holdings Co., Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.92%
12-Months-Change
Fundamentals
Return on Equity
0.60%
Trailing 12-Months
Asset Growth
2.60%
Trailing 12-Months
Company Description
Hygeia Healthcare Holdings Co., Ltd.
Hygeia Healthcare Holdings Co., Limited (6078.HK) is a prominent oncology healthcare provider primarily operating across the People's Republic of China. The company owns and manages a network of private, for-profit hospitals specializing in comprehensive cancer care. These facilities offer a broad spectrum of services, including diagnostic procedures such as tumor screening and genetic analysis, advanced therapeutic interventions like radiotherapy, surgery, chemotherapy, immunotherapy, and targeted treatments, alongside crucial supportive care including oncology rehabilitation, nutritional guidance, and hospice services. Beyond direct patient care, Hygeia also provides consulting expertise for radiotherapy centers and licenses its specialized SRT (Stereotactic Radiotherapy) equipment, offering ongoing maintenance and technical support for these systems. The company's operations extend to providing hospital and corporate management services, as well as supply chain solutions. By the end of 2021, Hygeia Healthcare had established a significant presence, operating or managing 12 oncology-focused hospitals spread across 9 cities in 7 provinces throughout mainland China. Established in 2009, the company maintains its headquarters in Shanghai, PRC.
6078 Stock 12 Month Forecast
Average Price Target
HK$19.20
▲(51.32% Upside)
Technical Analysis
Aidigong Maternal & Child Health
―
Jinxin Fertility Group Ltd.
―
C-MER Eye Care Holdings Limited
―
Town Health International Medical Group Ltd.
―
Arrail Group Ltd.
―
Options Prices
Currently, No data available
---